• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    6/21/24 9:00:00 AM ET
    $BIVI
    $MOB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Aerospace
    Industrials
    Get the next $BIVI alert in real time by email

    ORLANDO, FL / ACCESSWIRE / June 21, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and Mobilicom Ltd. (NASDAQ:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 22, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Access the interviews in their entirety at:

    BioVie: https://www.redchip.com/assets/access/bivi_access

    Mobilicom: https://www.redchip.com/assets/access/mob_access

    In an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs targeting unmet medical needs in neurodegeneration and liver disease. BioVie's lead asset, bezisterim (formerly NE3107), has demonstrated the ability to modulate TNFα production, leading to significant clinical improvements. Patients treated with bezisterim experienced reduced inflammation and insulin resistance, improved motor control and "morning on" symptoms in Parkinson's disease (PD), enhanced cognition and function, and better brain imaging scans in Alzheimer's disease (AD), as well as reduced DNA methylation levels. The Company's strategic priorities include launching a Phase 2b trial for Parkinson's in Fall 2024, initiating a Phase 3 trial for Alzheimer's in mid-2025 with a new once-daily formulation of bezisterim, continuing partnering discussions for bezisterim's geographic rights, and commencing an ascites Phase 3 trial upon identifying a suitable partner.

    Oren Elkayam, Founder and CEO of Mobilicom, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Mobilicom presents a strong investment opportunity with its comprehensive and proprietary technology suite. The company's products, including SkyHopper Datalinks, Ground Control Systems, Mobile Mesh Networking, the ICE Cybersecurity Suite, and CONTROLiT cloud management, form the core 'brain' of drones, providing control, guidance, and cybersecurity. Mobilicom's intellectual property, comprising trade secrets and 34 patent claims across two patent families, underscores its innovation leadership. With a global footprint, the company has secured over 50 customers in 18 countries and achieved 50 "design wins," indicating significant market penetration and long-term revenue potential. Mobilicom generated 43% revenue growth with 59% gross margin in 2023, and ended the year with a strong cash balance of $8.4 million. Combined with a narrowing monthly burn rate, this affords Mobilicom a long cash runway to implement its strategic plans, capture market share, and ramp revenues.

    About BioVie Inc.

    BioVie Inc. (NASDAQ:BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of ERK and NFκB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of AD and PD. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. Food and Drug Administration ("FDA") Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com.

    About Mobilicom

    Mobilicom is a leading provider of cybersecure robust solutions for the rapidly growing defense and commercial drones and robotics market. Mobilicom's large portfolio of field-proven technologies includes cybersecurity, software, hardware, and professional services that power, connect, guide, and secure drones and robotics. Through deployments across the globe with over 50 customers, including the world's largest drone manufacturers, Mobilicom's end-to-end solutions are used in mission-critical functions.

    For investors, please use https://ir.mobilicom.com/
    For company, please use www.mobilicom.com

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

    Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

    Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

    Follow RedChip on Twitter: https://twitter.com/RedChip

    Follow RedChip on YouTube: https://www.youtube.com/@redchip

    Follow RedChip on Rumble: https://rumble.com/c/c-3068340

    Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-407-644-4256
    [email protected]

    SOURCE: RedChip



    View the original press release on accesswire.com

    Get the next $BIVI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BIVI
    $MOB

    CompanyDatePrice TargetRatingAnalyst
    BioVie Inc.
    $BIVI
    7/22/2022$7.00Overweight
    Cantor Fitzgerald
    BioVie Inc.
    $BIVI
    11/30/2021$50.00 → $27.00Buy
    B. Riley Securities
    More analyst ratings

    $BIVI
    $MOB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on BioVie Inc. with a new price target

      Cantor Fitzgerald initiated coverage of BioVie Inc. with a rating of Overweight and set a new price target of $7.00

      7/22/22 7:51:28 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities reiterated coverage on BioVie with a new price target

      B. Riley Securities reiterated coverage of BioVie with a rating of Buy and set a new price target of $27.00 from $50.00 previously

      11/30/21 8:23:48 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    $MOB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioVie Announces Data Highlighting Bezisterim's Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference

      CARSON CITY, Nev., July 09, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, presented "Bezisterim Epigenetic Effects on Aging and Neurodegeneration" at the 7th World Aging and Rejuvenation Conference (ARC-2025) taking place in Vienna, Austria, July 9th –10th, 2025. Unlike historical approach to Alzheimer's Disease (AD) treatment that focuses on changing one gene product (e.g., amyloid, p-Tau) at a time, bezisterim modulates inflammation and is believed to help reestablish homeostasis and small changes in

      7/9/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

      CARSON CITY, Nev., June 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the patient-centric design and accessibility of its ongoing SUNRISE-PD Phase 2 clinical trial will be presented at the Advanced Therapeutics in Movement & Related Disorders® Congress, to be held at National Harbor, MD, from June 27-30, 2025. People with Parkinson's disease (PD) often face barriers to accessing specialized care and participating in clinical trials due to delayed diagnos

      6/26/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mobilicom and Palladyne AI Partner to Deliver Cybersecure Autonomy for Drones, Industrial Robots and Other Unmanned Systems

      Each party to offer Palladyne™AI's embodied neuro-symbolic artificial intelligence Software bundled with Mobilicom's OS3 cybersecurity solution Palo Alto, California, and Salt Lake City, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Mobilicom Limited (Nasdaq: MOB, MOBBW) ("Mobilicom"), a provider of cybersecurity and robust solutions for drones and robotics, and Palladyne AI Corp. (NASDAQ:PDYN) ("Palladyne AI"), a developer of embodied neuro-symbolic artificial intelligence software for robotic platforms and unmanned systems in the defense and commercial sectors, today announced they entered a cooperation agreement to offer to their respective customers the bundled solution of Palladyne AI's

      6/26/25 7:00:00 AM ET
      $MOB
      $PDYN
      Aerospace
      Industrials
      Computer Software: Prepackaged Software
      Technology

    $BIVI
    $MOB
    SEC Filings

    See more
    • Amendment: SEC Form S-1/A filed by BioVie Inc.

      S-1/A - BIOVIE INC. (0001580149) (Filer)

      7/11/25 5:19:50 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-1 filed by BioVie Inc.

      S-1 - BIOVIE INC. (0001580149) (Filer)

      7/3/25 5:01:47 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Mobilicom Limited

      6-K - Mobilicom Ltd (0001898643) (Filer)

      6/30/25 4:15:12 PM ET
      $MOB
      Aerospace
      Industrials

    $BIVI
    $MOB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Do Cuong V bought 10,000 shares (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      3/6/24 5:12:41 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Do Cuong V bought $17,800 worth of shares (10,000 units at $1.78), increasing direct ownership by 17% to 68,759 units (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      12/1/23 6:26:32 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    $MOB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rogich Sigmund was granted 32,700 shares, increasing direct ownership by 774% to 36,926 units (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      1/7/25 5:26:37 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Berman Richard J was granted 34,200 shares, increasing direct ownership by 531% to 40,643 units (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      1/7/25 5:24:53 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sherman Michael Edward

      4 - BIOVIE INC. (0001580149) (Issuer)

      1/7/25 5:21:05 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    $MOB
    Leadership Updates

    Live Leadership Updates

    See more
    • Mobilicom Appoints Technology Executive Guy Givoni to its Board of Directors

      Givoni is a tech leader and senior executive with over two decades of experience building and scaling technology companies in the cybersecurity, drones, AI, B2B software and AgTech industries Palo Alto, California, June 05, 2025 (GLOBE NEWSWIRE) -- Mobilicom Limited (NASDAQ:MOB), a provider of cybersecurity and robust solutions for drones and robotics, today announced the appointment of Guy Givoni to its Board of Directors. Mr. Givoni previously served on Mobilicom's Advisory Board from 2017 through 2023. Mr. Givoni is a global business leader and senior executive with over 20 years of experience building and scaling technology companies in the cybersecurity, AI, UAV (uncrewed autonomo

      6/5/25 4:05:00 PM ET
      $MOB
      Aerospace
      Industrials
    • BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

      The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and cross-sector expertise to unlock value and reshape care in Alzheimer's, Parkinson's and other neuroinflammatory disorders CARSON CITY, Nev., May 05, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of its Corporate Advisory Board – a coalition of seven powerhous

      5/5/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mobilicom Reports 2024 Year-End Financial Results: Record Revenues Up 45%

      Revenue momentum continues with robust gross margins, reduced operating expenses Major recent wins expected to drive growth include the addition of Mobilicom's systems to the U.S. Department of Defense's (DoD) Blue UAS Framework and its OS3 cybersecurity software platform for AI-Driven drones and robotics Strong cash position of $8.6 million with low average monthly net burn rate of $267K provides a long cash runway to support growth PALO ALTO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Mobilicom Limited (Nasdaq: MOB), a provider of cybersecurity and robust solutions for drones and robotics, today announced financial results for the twelve months ended December 31, 2024, as well as rece

      3/27/25 4:15:24 PM ET
      $MOB
      Aerospace
      Industrials

    $BIVI
    $MOB
    Financials

    Live finance-specific insights

    See more
    • BioVie Announces Data Highlighting Bezisterim's Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference

      CARSON CITY, Nev., July 09, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, presented "Bezisterim Epigenetic Effects on Aging and Neurodegeneration" at the 7th World Aging and Rejuvenation Conference (ARC-2025) taking place in Vienna, Austria, July 9th –10th, 2025. Unlike historical approach to Alzheimer's Disease (AD) treatment that focuses on changing one gene product (e.g., amyloid, p-Tau) at a time, bezisterim modulates inflammation and is believed to help reestablish homeostasis and small changes in

      7/9/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

      CARSON CITY, Nev., June 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the patient-centric design and accessibility of its ongoing SUNRISE-PD Phase 2 clinical trial will be presented at the Advanced Therapeutics in Movement & Related Disorders® Congress, to be held at National Harbor, MD, from June 27-30, 2025. People with Parkinson's disease (PD) often face barriers to accessing specialized care and participating in clinical trials due to delayed diagnos

      6/26/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

      CARSON CITY, Nev., June 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the decentralized design and patient experience of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in poster session at the upcoming Advanced Therapeutics in Movement & Related Disorders® Congress, to be held at National Harbor, MD, from June 27 to June 30, 2025. Details for the poster session are as follows: Title: SUN

      6/24/25 4:05:00 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    $MOB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mobilicom Limited

      SC 13G/A - Mobilicom Ltd (0001898643) (Subject)

      11/13/24 5:28:41 PM ET
      $MOB
      Aerospace
      Industrials
    • SEC Form SC 13G filed by BioVie Inc.

      SC 13G - BIOVIE INC. (0001580149) (Subject)

      10/25/24 4:01:25 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BioVie Inc.

      SC 13D/A - BIOVIE INC. (0001580149) (Subject)

      6/25/24 7:47:33 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care